Amicus Therapeutics Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Maybe just on sort of Pompe launch preparation. Maybe first, if you could give the latest color in terms of how the EAP is going in the U.K.? And maybe any color in terms of uptake and physician feedback there? And then just thinking towards the U.S., maybe just if you could give color on your expectations for uptake in patients that have already, maybe started on neoGAA and how you're thinking about sort of uptake in the ERT-switch patients as well as potentially switches from neoGAA and any initial thoughts there?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : I wanted to ask outside of all the additional findings that you've presented and published on AT-GAA since the PROPEL readout, what else gives you confidence heading into this decision, but then also in the role that AT-GAA could place in the market. So for example, at around the agency commentary on the unmet need to the EAMS, next Myozyme labeled. And then also publications around the different endpoints. So for example, I know in the past, you really emphasized some of the newer work on SBC and the understanding around mortality risk.

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : Can you remind us the size of the sales force that you have in the U.S. and in Europe? Did you -- or do you plan to increase the size in preparation for the AT-GAA launch? And also given that it's still an IV infusion, not like the oral for Galafold, do you expect that you still have to face some type of, call it, related challenges when you launch AT-GAA?